Bristol Myers Squibb Company
NEWS
Bristol Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab) as an adjuvant treatment for localized renal cell carcinoma (RCC) failed to hit the primary endpoint.
As the second financial quarter of the year comes to a close, pharma and biotech companies are releasing their financial results. For more information on the top-earning companies, read on.
As the calendar pages continue to turn, the FDA has a slew of novel drugs awaiting approval, several of which are likely to become game-changers for patients and key assets for companies.
BMS’ CAR-T therapy Breyanzi picked up a second approval from the FDA. The cancer drug was approved for the treatment of adult patients with large B-cell lymphoma.
A new report by PwC projects that the second half of this year will see a “flurry of deals activity across all areas of the sector.”
BMS, TG Therapeutics, Spero and Merck are all preparing for PDUFA dates over the next couple of weeks. Here’s a closer look.
Evotec SE has inked a deal with Janssen Pharmaceutical hat showcases its end-to-end integrated drug discovery and development platform.
Owkin and BMS signed a deal to utilize Owkin’s artificial intelligence capabilities to carry out more targeted and efficient clinical trials on a wide range of therapeutic candidates.
Novo Nordisk and Eli Lilly came under legal scrutiny this week, while BMS forked over $11 million to settle claims over anticompetitive tactics.
JOBS
IN THE PRESS